Grant: CIHR Clinician Scientist - Phase 2
Université Laval
$180,000.00
Identification of Novel Prognostic Biomarkers in Stem cell Transplantation and Prostate Cancer
EF 2012-13
Résumé
One of the greatest challenges of the fields of hematology and oncology is to optimize and personalize patient care to overcome the high rate of life-threatening complications and the overall cancer-related mortality. There are also significant limitations in our ability to predict cancer progression or any other adverse events related to treatment approaches. For instance, risk of disease progression and mortality differs greatly between individuals, and the variability in clinical outcome further emphasizes the need to find novel prognostic markers in almost all types of cancer. Consequently, there is a clear unmet hemato-oncological needs to better predict cancer outcomes, and thus far, very few prognostic markers fill this gap in knowledge, particularly in the two areas of the research program; 1) life-threatening complications after stem cell transplantation used to treat cancer patients and 2) prostate cancer (PCa). With this goal in mind, the research program focuses on the discovery of inherited molecular markers to help predict clinical outcome in these specific areas of research. Indeed, a better knowledge of the underlying physiological basis for those critical individual differences is therefore essential in order to minimize risks for adverse events, to prevent toxicity and to personalize treatment. This research program is expected to generate novel prognostic biomarkers with a high translational potential with impending clinical application.
Programme
CIHR Clinician Scientist - Phase 2
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
277736
Name
Levesque Eric
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Clinical
Prcname2
Clinician Scientist
Projecttitle
Identification of Novel Prognostic Biomarkers in Stem cell Transplantation and Prostate Cancer
Programtype2
Salary Programs
Orgnameinp2
Université Laval
Cihramount2
$180,000
Cihrequipment2
$0
Programname2
CIHR Clinician Scientist - Phase 2
Keyworddelim
Germline Variations; Graft-Vs-Host Disease; Immunosuppressants; Polymorphisms; Prognostic Biomarkers; Prostate Cancer; Stem Cell Transplantation; Steroid Hormones
Abstract
One of the greatest challenges of the fields of hematology and oncology is to optimize and personalize patient care to overcome the high rate of life-threatening complications and the overall cancer-related mortality. There are also significant limitations in our ability to predict cancer progression or any other adverse events related to treatment approaches. For instance, risk of disease progression and mortality differs greatly between individuals, and the variability in clinical outcome further emphasizes the need to find novel prognostic markers in almost all types of cancer. Consequently, there is a clear unmet hemato-oncological needs to better predict cancer outcomes, and thus far, very few prognostic markers fill this gap in knowledge, particularly in the two areas of the research program; 1) life-threatening complications after stem cell transplantation used to treat cancer patients and 2) prostate cancer (PCa). With this goal in mind, the research program focuses on the discovery of inherited molecular markers to help predict clinical outcome in these specific areas of research. Indeed, a better knowledge of the underlying physiological basis for those critical individual differences is therefore essential in order to minimize risks for adverse events, to prevent toxicity and to personalize treatment. This research program is expected to generate novel prognostic biomarkers with a high translational potential with impending clinical application.
Competitiondate
201301
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Levesque, Eric
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $180,000~ $0~